CML
EMA keeps Ariad cancer drug on the market
October 13, 2014Sales and Marketing Ariad, CML, EMA, PRAC, iclusig, leukaemia, ponatinib
The EMA has recommended Ariad’s leukaemia drug Iclusig (ponatinib) should continue to be used under its current indication despite ongoing …
PMCPA raps Pharmaxis
June 16, 2014Manufacturing and Production, Sales and Marketing ABPI, CML, PMCPA, pharmaxis
Pharmaxis Pharmaceuticals has been given the most severe punishment that the PMCPA can hand out following a series of breaches …
CLL drug achieves ‘unprecedented’ remissions
December 9, 2013Research and Development, Sales and Marketing AbbVie, CML, Genentech, abt-199
AbbVie and Genentech’s investigational oncology drug ABT-199 has performed well in a Phase I trial for blood cancer, according to …
NICE rejects Bosulif
November 28, 2013Sales and Marketing CML, NHS, NICE, Pfizer, bosulif
In a blow for Pfizer NICE has categorically rejected the manufacturer’s Bosulif as a treatment for previously-treated chronic myeloid leukaemia …
Ariad ditches CML trial
October 21, 2013Research and Development, Sales and Marketing Ariad, CML, iclusig
Ariad Pharmaceuticals has ditched its late-stage trial of Iclusig in patients with newly-diagnosed chronic myeloid leukemia (CML) after blood clots …
NICE rejects Pfizer blood cancer drug
July 16, 2013Sales and Marketing BMS, CML, NICE, Pfizer, bosulif
NICE is not recommending Pfizer’s blood cancer drug Bosulif due to uncertainties over its cost effectiveness and survival benefit. In …
CHMP nod for Pfizer CML drug
January 21, 2013Sales and Marketing CHMP, CML, FDA, Pfizer
Pfizer’s cancer drug bosutinib has been given a positive opinion by the CHMP for patients with chronic myelogenous leukemia (CML). …
Private equity firm pays $212m for Cambridge Major Labs
January 16, 2013Manufacturing and Production American Capital, CML, Cambridge
Private equity firm American Capital has said it will pay $212 million to buy out Cambridge Major Laboratories (CML), a …
Double approval for Pfizer cancer drugs
September 6, 2012Sales and Marketing CML, Cancer, Glivec, Pfizer, axitinib, rcc
Two cancer drugs from Pfizer have been approved, one in Europe for kidney cancer and another in the US for …
Ariad files new blood cancer drug with the FDA
July 31, 2012Research and Development, Sales and Marketing Ariad, CML, EMA, FDA, Glivec, blood cancer
Ariad has filed its investigational blood cancer drug ponatinib with the FDA and hopes for an accelerated review. The US …
Ariad touts next generation CML treatment
June 29, 2012Research and Development, Sales and Marketing Ariad, CML, Cancer, Europe, Switzerland
Ariad Pharmaceuticals is to expand into Europe following promising results for an investigational cancer drug. The US biotech firm will …
Trial hitch for Pfizer’s leukaemia drug submission plans
December 7, 2010Research and Development, Sales and Marketing CML, Gleevec, Glivec, Pfizer, bosutinib, chronic myeloid leukaemia
Pfizer is pressing ahead with plans to submit bosutinib for European approval despite the chronic myeloid leukaemia drug missing its …
Latest content
Scots neonatal innovations target hearing loss and earlier care
Agentis Health Group acquires Clinical Pharmacist Solutions
